{"title":"葛兰素史克的Stiefel实验室收购Welichem生物技术公司的中期牛皮癣和特应性皮炎药物","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i6.1749","DOIUrl":null,"url":null,"abstract":"GlaxoSmithKline’s Stiefel Laboratories has agreed to acquire worldwide development and commercialisation rights to Welichem Biotech’s WBI-1001, a topical anti-inflammatory agent in Phase II development for psoriasis and atopic dermatitis. Welichem will receive an initial payment of CAD$35 M (US$34 M) and is also eligible to receive additional payments contingent upon clinical development and commercial accomplishments related to WBI-1001. The deal will initially exclude rights to the drug in China, Taiwan, Macao and Hong Kong.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i6.1749\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"GlaxoSmithKline’s Stiefel Laboratories has agreed to acquire worldwide development and commercialisation rights to Welichem Biotech’s WBI-1001, a topical anti-inflammatory agent in Phase II development for psoriasis and atopic dermatitis. Welichem will receive an initial payment of CAD$35 M (US$34 M) and is also eligible to receive additional payments contingent upon clinical development and commercial accomplishments related to WBI-1001. The deal will initially exclude rights to the drug in China, Taiwan, Macao and Hong Kong.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i6.1749\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i6.1749","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug
GlaxoSmithKline’s Stiefel Laboratories has agreed to acquire worldwide development and commercialisation rights to Welichem Biotech’s WBI-1001, a topical anti-inflammatory agent in Phase II development for psoriasis and atopic dermatitis. Welichem will receive an initial payment of CAD$35 M (US$34 M) and is also eligible to receive additional payments contingent upon clinical development and commercial accomplishments related to WBI-1001. The deal will initially exclude rights to the drug in China, Taiwan, Macao and Hong Kong.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
